Clinical Trials Browser

Phase 2/3 × Not yet recruiting × apatinib × Clear all

NCT07309419 2025-12-30

Cocktail-001

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06796803 2025-02-10

Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular